Cencora (NYSE:COR) Given New $419.00 Price Target at JPMorgan Chase & Co.

Cencora (NYSE:COR) had its price target increased by JPMorgan Chase & Co. from $417.00 to $419.00 in a research note released on Tuesday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other research firms have also issued reports on COR. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Mizuho boosted their price target on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Bank of America decreased their price objective on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research report on Monday, January 5th. Finally, Wells Fargo & Company increased their target price on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and an average price target of $396.92.

Cencora Trading Down 0.9%

Shares of COR stock opened at $360.00 on Tuesday. Cencora has a fifty-two week low of $237.71 and a fifty-two week high of $377.54. The company has a 50 day moving average price of $346.17 and a 200 day moving average price of $327.39. The stock has a market capitalization of $69.84 billion, a P/E ratio of 43.27, a price-to-earnings-growth ratio of 1.67 and a beta of 0.68. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating the consensus estimate of $4.04 by $0.04. The company had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm’s revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the company posted $3.73 EPS. Equities research analysts predict that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is presently 28.85%.

Insider Transactions at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 20,316 shares of company stock worth $7,151,265 over the last 90 days. 0.38% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Cencora

A number of hedge funds have recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares during the period. Oakworth Capital Inc. purchased a new position in Cencora in the fourth quarter worth $26,000. Elyxium Wealth LLC acquired a new stake in Cencora in the fourth quarter valued at $27,000. Archer Investment Corp boosted its position in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares in the last quarter. Finally, IAG Wealth Partners LLC acquired a new position in shares of Cencora during the 3rd quarter worth $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Trending Headlines about Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: JPMorgan raised its price target to $419 and kept an “overweight” rating, implying roughly mid‑teens upside from current levels — a notable analyst endorsement that can support the stock. Benzinga
• Positive Sentiment: Cencora selected a new $106M distribution site in Greater Cincinnati (Hillwood), expanding logistics capacity that should support revenue growth and margin improvement over time. Cincinnati Business Journal
• Positive Sentiment: Pharma distribution wins: SQ Innovation’s Lasix ONYU gained access to major U.S. distributors, including Cencora, which could provide incremental product revenue and market‑access momentum. Yahoo Finance
• Neutral Sentiment: Cencora updated its segment reporting following a strategic business review; this improves disclosure but may temporarily complicate comparability to prior periods. TipRanks
• Neutral Sentiment: The company’s ~$2B physician‑group buyout is being framed as a strategic move into provider services; it supports growth strategy but carries integration risk and financing implications. Becker’s ASC
• Neutral Sentiment: Non‑financial/PR items such as executive recognition and analyst‑target aggregation pages surfaced; these are low impact on near‑term valuation. Yahoo Finance — Corporate Purpose
• Negative Sentiment: Cencora priced $3.0 billion of senior notes across five tranches (2029–2056) with coupons from 3.95% to 5.65% — a large debt raise that increases gross leverage and future interest expense; given the company’s already elevated debt metrics, the bond sale is the clearest near‑term headwind for the stock. Business Wire Yahoo Finance

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.